Compare APT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | SCLX |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 55.1M |
| IPO Year | 1997 | 2020 |
| Metric | APT | SCLX |
|---|---|---|
| Price | $5.46 | $6.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 68.4K |
| Earning Date | 05-08-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $59,142,000.00 | $30,253,000.00 |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | N/A | $186.30 |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $4.34 | $4.20 |
| 52 Week High | $7.50 | $34.27 |
| Indicator | APT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 43.76 |
| Support Level | $5.49 | $6.23 |
| Resistance Level | $5.69 | $7.24 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 91.18 | 49.49 |
Alpha Pro Tech Ltd is in the business of protecting people, products, and environments. It is developing, manufacturing, and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical, and dental markets. It also manufactures a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply, consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment, and synthetic roof underlayment accessories.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.